<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome</td>
<td>3</td>
</tr>
<tr>
<td>Objectives</td>
<td>4</td>
</tr>
<tr>
<td>Practical Information</td>
<td>5</td>
</tr>
<tr>
<td>Time Zones</td>
<td>6</td>
</tr>
<tr>
<td>Committees</td>
<td>8</td>
</tr>
<tr>
<td>Programme</td>
<td>13</td>
</tr>
<tr>
<td>Acknowledgement</td>
<td>24</td>
</tr>
</tbody>
</table>
Dear Colleagues,

Welcome to the 14th INTEREST Conference November 30-December 4, 2020 and the conference pre-week November 23-27!

Since 2014, we have dedicated the annual INTEREST Conference to the memory of Professor Joep Lange and Jacqueline van Tongeren of the Amsterdam Institute for Global Health and Development. Pivotal in establishing the INTEREST conference as a leading African and international forum for the dissemination of HIV science and practice, they died tragically when Malaysian Airlines flight MH17 was shot down over Ukraine on July 17, 2014.

The INTEREST Conference is now a recognised fixture in the HIV conference calendar. It focuses on HIV treatment, pathogenesis, and prevention in resource-limited settings, particularly in Africa. Young researchers and established international HIV experts share original research and state-of-the-art reviews on a wide range of HIV and related topics. In light of the SARS-CoV-2 pandemic, the 14th INTEREST conference was initially postponed from the face-to-face conference that had been planned for Windhoek, Namibia in May to the first week of December. A decision was made in late August 2020 to move to a virtual format, which has proven to be a wise move, given that the pandemic is continuing to expand as INTEREST pre-week activities are about to start.

The 14th INTEREST conference offers lectures, abstract-driven oral and poster sessions, and symposia but this year there will be no debates or meet-the-expert lunches. The main conference programme runs from 13:30-16:30 South Africa standard time November 30 -December 4. The pre-week November 23rd to 27th includes pre-meetings, a scientific writing skills building workshop, and poster gallery viewing. Parallel sessions on Wednesday the 25th, Thursday the 26th, and Friday 27th offer 3 activities: 1) guided poster tours, 2) Joep Lange mentoring sessions, and 3) grantspersonship sessions.

Namibia has been playing a significant role in HIV scientific advances on the African continent. It is appropriate that scientists, clinicians, program managers, students, and others from across Africa can get acquainted and appreciate the efforts that Namibia has made in combating HIV.

We hope that you will actively participate in virtual networking with Namibian, regional, and international conference participants through the INTEREST conference platform.

We wish you an enjoyable and educational conference!

Conference Chairs 2020
Meeting Objectives

The INTEREST Conference aims to:

• Provide cutting-edge knowledge in the fields of treatment, pathogenesis, and prevention of human immunodeficiency virus (HIV) and related infections and chronic conditions;

• Exchange ideas on how to provide and support HIV testing services and clinical care provision to adults, adolescents, and children living with HIV in Africa to achieve 95-95-95 goals;

• Foster new research interactions among leading investigators and those who represent the potential future scientific leadership of health care and research on the African continent;

• Expand our focus on capacity building and implementation science.

Learning Objectives

After attending INTEREST, conference participants will:

• Have an improved knowledge of the most recent findings in HIV treatment, pathogenesis, and prevention research;

• Better understand the social determinants of health and HIV risk in order to contribute optimally to national, local, and individual HIV prevention strategies;

• Have learned about current guidelines and policies, as well as innovative programmes across the continent that are addressing HIV;

• Recognize challenges in the screening, monitoring, and diagnosis of patients living with HIV and be able to integrate the latest scientific results into daily clinical care to improve the quality of life of individuals living with HIV.
Practical Information

Abstracts
Accepted abstracts are published in *Reviews in Antiviral Therapy & Infectious Diseases, Volume 2020_10.*
You can download the abstract book here.

Certificate of Attendance
Certificates of attendance will be sent by e-mail in the week following the Conference after completion of the Feedback Forms.

Exhibition
Visiting the exhibition booths in the exhibition area will give you the opportunity to meet and network with key suppliers and industry leaders. This will help keep you up-to-date with the latest industry developments.

Feedback Forms
Your feedback is very valuable to us and enables us to further improve this conference. After each session a short questionnaire will pop-up and we would like ask you to take a minute to complete it. After the conference, a survey will be send to you via email, with other questions to improve this conference.

Group Picture
We ask you all to take a photo of yourself and send it to the INTEREST secretariat at rikke@vironet.com or lara@amededu.com. They will stitch it all together and send out the finished virtual group photo at the end of the conference.

Networking
Meet the other delegates by going to the networking area. Here you can join the general chat or chat with other delegates about certain topics like you would do at an actual conference.

Poster Gallery & Poster Viewing
During the virtual conference all accepted posters are displayed in the E-Posters Area. The E-Posters Area is always open for you.

Presentations and Webcasts
Webcasts of the presentations along with the PDF presentations will be available on www.AcademicMedicalEducation.com
3 weeks after the meeting. You will be able to watch the presentations on the workshop portal until 3 weeks after the workshop: https://interest2020.com/.

Social Media
We encourage you to post news about INTEREST to your social media accounts and tweet about INTEREST as often as you like during the conference. You can either post your own tweet to your followers using the hashtag #INTEREST2010 or retweet a message through the official @INTERESTconf account.

Technical Problems
Should you encounter any technical problems, please contact us at rikke@vironet.com or lara@amededu.com.

Time Zones
Times are in Central Africa Time (CAT) / South African Standard Time (SAST). If you need to convert the times to your timezone, this website might be of interest to you: https://www.worldtimebuddy.com/

Disclaimer: This Conference aims to offer participants the opportunity to share information. The Organisers of this conference, AIGHD and Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims that may result from the use of information or publications from this Conference.
## Time Zones

### MONDAY 30 NOVEMBER

<table>
<thead>
<tr>
<th>Event</th>
<th>EST</th>
<th>WAT/CET</th>
<th>SAST/EET</th>
<th>EAT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Session 1</td>
<td>06:30</td>
<td>12:30</td>
<td>13:30</td>
<td>14:30</td>
</tr>
<tr>
<td>Oral Abstract Presentations 1</td>
<td>07:35</td>
<td>13:35</td>
<td>14:35</td>
<td>15:35</td>
</tr>
<tr>
<td>Symposium - JnJ</td>
<td>08:35</td>
<td>14:35</td>
<td>15:35</td>
<td>16:35</td>
</tr>
</tbody>
</table>

### TUESDAY 1 DECEMBER

<table>
<thead>
<tr>
<th>Event</th>
<th>EST</th>
<th>WAT/CET</th>
<th>SAST/EET</th>
<th>EAT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Session 2</td>
<td>06:30</td>
<td>12:30</td>
<td>13:30</td>
<td>14:30</td>
</tr>
<tr>
<td>Mini-Oral Abstract Presentations 1</td>
<td>07:35</td>
<td>13:35</td>
<td>14:35</td>
<td>15:35</td>
</tr>
<tr>
<td>Symposium - MSD</td>
<td>08:35</td>
<td>14:35</td>
<td>15:35</td>
<td>16:35</td>
</tr>
</tbody>
</table>

### WEDNESDAY 2 DECEMBER

<table>
<thead>
<tr>
<th>Event</th>
<th>EST</th>
<th>WAT/CET</th>
<th>SAST/EET</th>
<th>EAT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symposium - AbbVie</td>
<td>06:30</td>
<td>12:30</td>
<td>13:30</td>
<td>14:30</td>
</tr>
<tr>
<td>Symposium - ViiV</td>
<td>08:35</td>
<td>14:35</td>
<td>15:35</td>
<td>16:35</td>
</tr>
</tbody>
</table>

### THURSDAY 3 DECEMBER

<table>
<thead>
<tr>
<th>Event</th>
<th>EST</th>
<th>WAT/CET</th>
<th>SAST/EET</th>
<th>EAT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Session 3</td>
<td>06:30</td>
<td>12:30</td>
<td>13:30</td>
<td>14:30</td>
</tr>
<tr>
<td>Session 4</td>
<td>08:35</td>
<td>14:35</td>
<td>15:35</td>
<td>16:35</td>
</tr>
</tbody>
</table>

### FRIDAY 4 DECEMBER

<table>
<thead>
<tr>
<th>Event</th>
<th>EST</th>
<th>WAT/CET</th>
<th>SAST/EET</th>
<th>EAT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Session 5</td>
<td>06:30</td>
<td>12:30</td>
<td>13:30</td>
<td>14:30</td>
</tr>
<tr>
<td>IAS Session</td>
<td>08:35</td>
<td>14:35</td>
<td>15:35</td>
<td>16:35</td>
</tr>
</tbody>
</table>
Amsterdam Institute for Global Health and Development

The Amsterdam Institute for Global Health and Development (AIGHD) is an international research and education institute that works to develop sustainable solutions to major health problems. By taking a problem-oriented approach, AIGHD transcends the boundaries of traditional academic disciplines and integrates three fundamental activities into one institute: research, education, and policy. Founded by the late Professor Joep Lange in 2009, AIGHD brings together experts from multiple disciplines including biomedicine, economics, and social and behavioral sciences to address the most critical medical, social, economic, and political challenges in global health and development.

Virology Education

Virology Education (VE) is a leading provider of top quality, accredited programs for scientific interchange, knowledge sharing, and healthcare professional education. VE supports the healthcare community in discovering, researching, treating, and ultimately, curing viruses and infectious diseases. VE identifies needs, drives new initiatives, designs tailored programs, develops educational and scientific content, and handles logistical program management. Using a network of leading global experts, a database of 26,000 opt-in subscribers, and an in-house team of skilled professionals, Virology Education produces relevant, high-level content within the fields of HIV, hepatitis, co-infections, tuberculosis, emerging viruses, non-alcoholic steatohepatitis, liver disease, pharmacology, and oncology.
Local Organising Committee

Ismael Katjite - National Technical Advisory Committee of the HIV/AIDS Response, Namibia
Anne-Marie Nitschke - Ministry of Health and Social Services, Namibia
Ndapewa Hamunime - Ministry of Health and Social Services, Namibia
Julieth Karirao - Ministry of Health and Social Services, Namibia
Norbert Forster - International Training & Education Center for Health, Namibia
Hilma Nangombe - Ministry of Health and Social Services, Namibia
Abigail Solomons - Positive Vibes Trust, Namibia
Veronica Theron - Office of the First Lady, Namibia
Leonard Bikenese - Ministry of Health and Social Services, Namibia
Fransina Frans - Ministry of Health and Social Services, Namibia
Tadesse Mekonen - Avacare Global, Namibia
David Uirab - Namibia Institute of Pathology, Namibia
Flavia Mugala Mukungu - Namibian HIV Clinicians Society, Namibia
Petrina Kapewangolo - University of Namibia, Namibia
Awafulo Omotayo - Namibia University of Science and Technology, Namibia
Honourable Dr. Kalumbi Shangula - Minister of Health and Social Services, Namibia
Anne-Marie Nitschke
Ministry of Health and Social Services, Namibia
Local Chair 2020

Catherine Hankins
MD, PhD, FRCPC
Amsterdam Institute for Global Health and Development, Canada / The Netherlands
Scientific Chair

Charles Boucher
MD, PhD
Erasmus Medical Center, Rotterdam, The Netherlands
Co-Founder

Elizabeth Bukusi
MBChB, MD, MPH, PhD
Kenya Medical Research Institute, Kenya

Pierre-Marie Girard
MD, PhD
Hôpital Saint-Antoine, Université Pierre et Marie Curie, France

Andrew Kambugu
MBChB, MMed
Infectious Diseases Institute, Makerere University College of Health Sciences, Uganda

Ismael Katjitae
MD, MMed
National Technical Advisory Committee of the HIV/AIDS Response, Namibia
Local Chair 2020

Elly Katabira
MD, FRCP
Makarere University College of Health Sciences, Uganda
Co-Chair

Linda-Gail Bekker
MBChB, FCP, PhD
Desmond Tutu HIV Foundation, University of Cape Town, South Africa

Guido Ferrari
MD
Duke University Medical Center, United States

James Hakim
MD
University of Zimbabwe College of Health Sciences, Zimbabwe

Peter Kilmarx
MD, FACP, RADM
National Institutes of Health, Fogarty International Center, United States

Conference Organisers
International Conference Committee
International Conference Committee

Nagalingeswaran Kumarasamy
MD
YRG Centre for AIDS Research and Education, India

Chewe Luo
MD, PhD
UNICEF, United States / University Teaching Hospital, Zambia

Sam Phiri
DCM, PhD, MSc
Partners in Hope Malawi

Coumba Touré Kane
PharmD, PhD
Laboratoire de Bacteriologie-Virologie CHU Le Dantec, Dakar University, Senegal

Stephen Watiti
MD
Mildmay Hospital, Uganda

Kwasi Torpey
MD
University of Ghana, Ghana

Timothy Mastro
MD, FACP, DTM&H
FHI 360, University of North Carolina at Chapel Hill, United States

Anna Laura Ross
PhD
UNITAID, Switzerland

François Venter
MBCCH, MMEd, FCP (SA), DTM&H
University of the Witwatersrand, South Africa

Stephen Watiti
MD
Mildmay Hospital, Uganda
Emeritus Group

Serge Eholié, MD, PhD - CHU de Treichville, University of Abidjan, Ivory Coast
Grace John-Stewart, MD, PhD, - University of Washington, United States
Saidi Kapiga, MD, MPH, ScD - Mwanza Intervention Trials Unit (NIMR)/LSHTM, Tanzania / United Kingdom
Sinata Koulla, MD - Ministry of Health, Cameroon
Richard Koup, MD - Vaccine Research Center, National Institute of Allergy and Infectious Diseases [NIAID], United States
Sabin Nsanzimana, MD, PhD - Rwanda Biomedical Center, Rwanda
Anton Pozniak, MD - Chelsea and Westminster Hospital NHS Foundation Trust and Imperial College of London, United Kingdom
Helen Rees, MD – WITS Reproductive Health and HIV Institute [WRHI], University of the Witwatersrand, South Africa
Robert Schooley, MD - University of California, United States
Mauro Schechter, MD, PhD - Federal University Rio de Janeiro, Brazil
Stefano Vella, MD – Istituto Superiore di Sanità, Italy
Debrework Zewdie, PhD - CUNY School of Public Health and Public Policy, United States

Our Team

Karin Siebelt
Project Manager
karin@vironet.com

Marloes Nijboer
Project Manager
m.nijboer@aighd.org

Rikke Rode
Project Coordinator
rikke@vironet.com

Jacqueline Weiner
Communications Manager
j.weiner@aighd.org

Lara Da Sliva Miguel
Project Coordinator
lara@amededu.com
MONDAY, 30 NOVEMBER

Times are in South African Standard Time (SAST) / Central African Time (CAT)

13:30 Welcome from the Conference Co-chairs
Anne-Marie Nitschke - Local Chair
Ministry of Health and Social Services, Namibia
Ismael Katjitae - Local Chair
National Technical Advisory Committee of the HIV/AIDS response, Namibia
Elly Katabira, MD, FRCP - Co-Chair
Makerere University College of Health Sciences, Uganda
Catherine Hankins MD, PhD, FRCP, CM - Scientific Chair
Amsterdam Institute for Global Health and Development, Canada / The Netherlands
Honorable Dr. Kalumbi Shangula
Minister of Health & Social Services, Namibia

Session 1 - Opening
Chairs: Elly Katabira (Uganda) and Catherine Hankins (Canada / The Netherlands)

13:35 Introduction
Elly Katabira, MD, FRCP
Makerere University College of Health Sciences, Uganda
Catherine Hankins, MD, PhD, FRCPC, CM
Amsterdam Institute for Global Health and Development, Canada / The Netherlands

13:36 Impact of COVID-19 on HIV, Tuberculosis, and Malaria Epidemiology and Treatment Services Across Africa
John Nkengasong, MSc, PhD
Director of the Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia

13:51 HIV and Climate Change: the Research Opportunities
Matthew Chersich, MBBCh, MSc, PhD
University of the Witwatersrand, South Africa

14:06 Q & A

14:20 Tea Break

Oral Abstract Presentations 1
Chairs: Elizabeth Bukusi (Kenya) and Peter Kilmarx (United States)

14:35 Introduction

Gregory Chang, United States #3

14:44 The Frequency and Yield of Cryptococcal Antigen Screening among Newly Diagnosed and Anti-Retroviral Therapy Experienced HIV Patients in Rural Uganda
Joseph Baluku, Uganda #4

14:52 Cost-Utility Analysis of Dolutegravir-Versus Efavirenz 400mg-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon: 96-week Results from the NAMSAL ANRS 12313 Trial
Marwan al Qays Bousmah, France #2

15:00 What Shapes Resilience Among People Living with HIV? A Multi-Country Analysis of Data from the PLHIV Stigma Index 2.0
Stella Kentusi, Uganda #1

15:08 Q & A
15:20  Tea Break

**Symposium 1 - Johnson & Johnson - Innovations in the prevention and treatment of HIV**
*Chair: Yunus Moosa [South Africa]*

15:35  **Welcome, Introduction and Objectives**
Yunus Moosa  
South Africa

15:37  **Understanding Innovations in HIV Prevention**
Francois Venter  
South Africa

15:49  **Understanding Innovations in HIV Treatment**
Kogieleum Naidoo  
South Africa

16:01  **Group discussion: Practical considerations what can be done to ensure that vulnerable populations and young people benefit from such innovations?**

16:16  **Close**

16:20  **Closure Day 1**

Catherine Hankins MD, PhD, FRCPC, CM  
Amsterdam Institute for Global Health and Development, Canada / The Netherlands
## TUESDAY, 1 DECEMBER

*Times are in South African Standard Time (SAST) / Central African Time (CAT)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30</td>
<td>Welcome to Day 2</td>
</tr>
<tr>
<td></td>
<td><em>Ismael Katjitae</em></td>
</tr>
<tr>
<td></td>
<td>National Technical Advisory Committee of the HIV/AIDS response, Namibia</td>
</tr>
<tr>
<td>13:35</td>
<td><strong>Session 2 – HIV Prevention</strong></td>
</tr>
<tr>
<td></td>
<td><em>Chair: Elizabeth Bukusi (Kenya) and Timothy Mastro (United States)</em></td>
</tr>
<tr>
<td>13:35</td>
<td><strong>Introduction</strong></td>
</tr>
<tr>
<td></td>
<td><em>Elizabeth Bukusi, MBChB, MMed, MPH, PhD</em></td>
</tr>
<tr>
<td></td>
<td>Kenya Medical Research Institute, Kenya</td>
</tr>
<tr>
<td></td>
<td><em>Timothy Mastro, MD, FACP, DTM&amp;H</em></td>
</tr>
<tr>
<td></td>
<td>FHI 360, United States</td>
</tr>
<tr>
<td>13:36</td>
<td><strong>Progress on New Antiretroviral Formulations and Monoclonal Antibodies for HIV Prevention</strong></td>
</tr>
<tr>
<td></td>
<td><em>Nyaradzo Mavis Mgodi, MBChB, MMed</em></td>
</tr>
<tr>
<td></td>
<td>University of Zimbabwe Clinical Trials Research Centre, Zimbabwe</td>
</tr>
<tr>
<td>13:51</td>
<td><strong>The ECHO Trial: What’s Next on Contraception and HIV: Policy, Practice, and Research?</strong></td>
</tr>
<tr>
<td></td>
<td><em>Margaret Phiri Kasaro, MBChB, MSc</em></td>
</tr>
<tr>
<td></td>
<td>University of North Carolina Global Project Zambia (UNC GPZ), Zambia</td>
</tr>
<tr>
<td>14:06</td>
<td><strong>Q &amp; A</strong></td>
</tr>
<tr>
<td>14:20</td>
<td>Tea Break</td>
</tr>
<tr>
<td>14:35</td>
<td><strong>Mini-Oral Abstract Presentations 1</strong></td>
</tr>
<tr>
<td></td>
<td><em>Chairs: Sam Phiri (Malawi) and Anne-Laura Ross (Switzerland)</em></td>
</tr>
<tr>
<td>14:35</td>
<td><strong>Introduction</strong></td>
</tr>
<tr>
<td>14:36</td>
<td><strong>Striving Towards HIV Epidemic Control through Reaching a Population in Correctional Facilities in Namibia</strong></td>
</tr>
<tr>
<td></td>
<td><em>Hilaria Ashivudhi, Namibia</em></td>
</tr>
<tr>
<td><em>#26</em></td>
<td></td>
</tr>
<tr>
<td>14:39</td>
<td><strong>Index-Linked HIV Testing for Children and Adolescents in Health Facility and Community-Based Settings in Zimbabwe: Findings from the B-GAP Study</strong></td>
</tr>
<tr>
<td></td>
<td><em>Chido Dziva Chikwari, Zimbabwe</em></td>
</tr>
<tr>
<td><em>#24</em></td>
<td></td>
</tr>
<tr>
<td>14:42</td>
<td><strong>Perceptions, Preferences and Access to Community-Based HIV Testing Services among Men who have Sex with Men (MSM) in Côte d’Ivoire</strong></td>
</tr>
<tr>
<td></td>
<td><em>Maxime Inghels, United Kingdom</em></td>
</tr>
<tr>
<td><em>#23</em></td>
<td></td>
</tr>
<tr>
<td>14:45</td>
<td><strong>It is Better if you are Going to Test Yourself...”: Attitudes, Test Preferences and Challenges of HIV Self-Testing among Female Sex Workers in eThekwini, South Africa: the Siyaphanta study</strong></td>
</tr>
<tr>
<td></td>
<td><em>Kedibone Sithole, South Africa</em></td>
</tr>
<tr>
<td><em>#33</em></td>
<td></td>
</tr>
<tr>
<td>14:48</td>
<td><strong>Traditional Healers Can Increase Uptake of HIV Testing among Adults of Unknown Serostatus: Results from a Cluster Randomized Pilot Study in Southwestern Uganda</strong></td>
</tr>
<tr>
<td></td>
<td><em>Radhika Sundararajan, United States</em></td>
</tr>
<tr>
<td><em>#37</em></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>-------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>14:54</td>
<td>Gaining Traction: Promising Shifts in Gender Norms and Intimate Partner Violence During an HIV prevention Trial in South Africa</td>
</tr>
<tr>
<td>14:57</td>
<td>Case Series of Urethrocutaneous Fistulas After Voluntary Medical Male Circumcision for HIV Prevention—15 African Countries, 2015–2019</td>
</tr>
<tr>
<td>15:00</td>
<td>Is the Use of Creatinine Clearance Test at Baseline for PrEP Enrolment Necessary in Resource-Constrained Settings?</td>
</tr>
<tr>
<td>15:03</td>
<td>Q &amp; A</td>
</tr>
<tr>
<td>15:20</td>
<td>Tea Break</td>
</tr>
<tr>
<td>15:35</td>
<td><strong>Symposium 2 - MSD - HIV in Africa: Challenges and Opportunities</strong></td>
</tr>
<tr>
<td>15:35</td>
<td>Opening and Welcome</td>
</tr>
<tr>
<td></td>
<td><strong>Desmond Tutu HIV Centre Institute of Infectious Disease and Molecular Medicine Faculty of Health Sciences University of Cape Town, South Africa</strong></td>
</tr>
<tr>
<td>15:36</td>
<td>PrEP: Where We Need to Go?</td>
</tr>
<tr>
<td></td>
<td><strong>Desmond Tutu HIV Centre Institute of Infectious Disease and Molecular Medicine Faculty of Health Sciences University of Cape Town, South Africa</strong></td>
</tr>
<tr>
<td>15:51</td>
<td>Treatment: Have we Reached the Final Mile</td>
</tr>
<tr>
<td></td>
<td><strong>Botswana Harvard AIDS Institute Partnership (MOH) University of Botswana School of Medicine Gaborone, Botswana</strong></td>
</tr>
<tr>
<td>16:06</td>
<td>Panel Discussion and Q &amp; A</td>
</tr>
<tr>
<td></td>
<td><strong>Desmond Tutu HIV Centre Institute of Infectious Disease and Molecular Medicine Faculty of Health Sciences University of Cape Town, South Africa</strong></td>
</tr>
<tr>
<td>16:20</td>
<td><strong>Closure Day 2</strong></td>
</tr>
<tr>
<td></td>
<td><strong>National Technical Advisory Committee of the HIV/AIDS response, Namibia</strong></td>
</tr>
</tbody>
</table>
WEDNESDAY, 2 DECEMBER

Times are in South African Standard Time (SAST) / Central African Time (CAT)

13:30  Welcome to Day 3
Elly Katabira, MD, FRCP
Makerere University College of Health Sciences, Uganda

Symposium 3 - AbbVie - Evolving HIV Clinical Pathway: Approaches to Combine Rapidly Changing Guidelines and Sustainability of Anti-Retroviral Treatment in Resource Limited Settings.
Chair: Andrew Kambugu (Uganda)

13:35  Opening and Welcome
Andrew Kambugu
Uganda

13:40  Speaker 1
Jeremy Nel
South Africa

13:55  Speaker 2
Albert Mwango
Zambia

14:10  Open Discussion, Q & A
All

14:19  Final Remarks & Closing
Andrew Kambugu
Makerere University College of Health Sciences, Uganda

14:20  Tea Break

Oral Abstract Presentations 2
Chairs: Flavia Mugala (Namibia) and James Hakim (Zimbabwe)

14:35  Introduction

14:36  Monitoring and Management of Treatment Failure Among People on Antiretroviral Therapy in Mozambique: Lessons Learned to Improve Treatment Effectiveness
Laura Marcela Torres, Mozambique #6

14:44  Rapid Antiretroviral Therapy Initiation and the Risk of Mortality and Loss to Follow-Up in Children with HIV
Peter James Elyanu, Uganda #7

14:52  High Levels of HIV Drug Resistance in Adult Patients with Unsuppressed Viral Load, Measured Through Routine Viral Load Programme Monitoring in South Africa, 2019
Gillian Hunt, South Africa #5

15:00  Effect of Same-Day ART Initiation on Early Retention in Rakai, Uganda
Jesca Basiima, Uganda #8

15:03  Q & A
# Symposium 4 - ViiV - The ART of Paediatric HIV: An African Perspective

*Chair: Michelle Kisare (Kenya)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:20</td>
<td>Tea Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:35</td>
<td><strong>Opening and Welcome</strong></td>
<td>Michelle Kisare</td>
<td>Kenya</td>
</tr>
<tr>
<td>15:40</td>
<td><strong>Evolution of Paediatric HIV Management in Africa</strong></td>
<td>Mark Cotton</td>
<td>South Africa</td>
</tr>
<tr>
<td>16:00</td>
<td><strong>The Role of Dolutegravir in Paediatric HIV Management</strong></td>
<td>Serufusa Sekidde</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>16:10</td>
<td><strong>Question and Answer session</strong></td>
<td>All</td>
<td></td>
</tr>
<tr>
<td>16:20</td>
<td><strong>Closure Day 3</strong></td>
<td>Elly Katabira, MD, FRCP</td>
<td>Makerere University College of Health Sciences, Uganda</td>
</tr>
</tbody>
</table>
**THURSDAY, 3 DECEMBER**

*Times are in South African Standard Time (SAST) / Central African Time (CAT)*

13:30  **Welcome to Day 4**  
Anne-Marie Nitschke - Local Chair  
Ministry of Health and Social Services, Namibia

---

**Session 3 - Access to Medicines and TB**  
*Chairs: Ndapewa Hamunime (Namibia) and Frank Cobelens (The Netherlands)*

13:35  **Introduction**  
Ndapewa Hamunime, MD, MBA  
Ministry of Health and Social Services, Namibia  
Frank Cobelens  
University of Amsterdam / Amsterdam Institute for Global Health and Development, The Netherlands

13:36  **What you Need to Know about Public-Health Licensing and Access to Medicines in Africa**  
Sébastien Morin  
Medicines Patent Pool, Switzerland

13:51  **TB State-of-the-Art: Implications for Africa**  
Dereck Tait, MBChB  
IAVI, South Africa

14:06  **Q & A**

14:20  **Tea Break**

---

**Mini-Oral Abstract Presentations 2**  
*Chairs: Catherine Hankins (Canada / The Netherlands) and Anton Pozniak (United Kingdom)*

14:35  **Introduction**

14:36  **Current Approaches for Identifying and Managing HIV Treatment Failure Among Children, Adolescents, and Young People In Sub-Saharan Africa: Multi-Country Experience from the New Horizons Collaborative**  
Natella Rakhmanina, United States  
#36

14:39  **Syndemic of Hepatitis B and C and Their Coinfection With HIV in Rwanda: Role of Unsafe Medical Practices and Sexual Behaviors**  
Jean Damascene Makuza, Rwanda  
#17

14:42  **Patient-Reported Outcomes After Direct-Acting Antiviral Treatment for Chronic Hepatitis C in West And Central Africa: The ANRS 12311 TAC Trial**  
Fabienne Marcellin, France  
#14

14:45  **Prevalence, Risk and Protective Factors for Common Mental Disorders Among Young People Living With HIV Compared to Their Uninfected Peers From the Kenyan Coast: A Cross Sectional Study**  
Moses Kachama Nyongesa, Kenya  
#29

14:48  **Trends in Transmitted Drug Resistance in A Cohort Of ART-Naive HIV-1 Infected Individuals in Ethiopia**  
Mulugeta Kiros, Ethiopia  
#16
### Programme

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:51</td>
<td>Using A Quality Improvement Collaborative Approach to Improve Tuberculosis Prevention Therapy Coverage in The Kavango Region, Namibia</td>
<td>Apollo Basenero, Namibia #32</td>
</tr>
<tr>
<td>14:54</td>
<td>For Each Hour a Patient Living with HIV Spends in the Health Facility, the Probability of Being Retained in Care Decreases: Results from a Patients’ Satisfaction Survey in Mozambique</td>
<td>Caroline De Schacht, Mozambique #12</td>
</tr>
<tr>
<td>14:57</td>
<td>Does Navigated Linkage to Care Work? A Cross-Sectional Study of Active Linkage to Care Within an Integrated Non-Communicable Disease</td>
<td>Kathryn Hopkins, South Africa #11</td>
</tr>
<tr>
<td>15:00</td>
<td>Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>15:20</td>
<td>Tea Break</td>
<td></td>
</tr>
<tr>
<td>15:35</td>
<td>Session 4 - STI and Implementation Science</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: François Venter (South Africa) and Kwasi Torpey (Ghana)</td>
<td></td>
</tr>
<tr>
<td>15:35</td>
<td>Introduction</td>
<td>François Venter, MBCCH, MMed, FCP (SA), DTM&amp;H</td>
</tr>
<tr>
<td></td>
<td></td>
<td>University of the Witwatersrand, South Africa</td>
</tr>
<tr>
<td>15:35</td>
<td></td>
<td>Kwasi Torpey, MD, PhD, MPH, FGCP</td>
</tr>
<tr>
<td></td>
<td></td>
<td>University of Ghana College of Health Sciences, Ghana</td>
</tr>
<tr>
<td>15:36</td>
<td>What’s New in Sexually Transmitted Infections and HIV in 2020</td>
<td>Rashida Ferrand, FRCP, PhD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>London School of Hygiene and Tropical Medicine / Biomedical Research and Training Institute, Zimbabwe</td>
</tr>
<tr>
<td>15:51</td>
<td>Implementation Science - an African Perspective</td>
<td>Peter Cherutich, MBChB, PhD, MPH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ministry of Health, Kenya</td>
</tr>
<tr>
<td>16:06</td>
<td>Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>16:20</td>
<td>Closure Day 4</td>
<td>Anne-Marie Nitschke</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ministry of Health and Social Services, Namibia</td>
</tr>
</tbody>
</table>

For Each Hour a Patient Living with HIV Spends in the Health Facility, the Probability of Being Retained in Care Decreases: Results from a Patients’ Satisfaction Survey in Mozambique. The study aimed to understand factors influencing patient retention in HIV care. The research involved a cross-sectional survey of patients in Mozambique, focusing on the association between time spent in the facility and retention rates. Key findings indicated a significant decrease in the probability of patients remaining in care over time, emphasizing the need for improved support mechanisms to enhance patient retention. This work underscores the importance of continuous evaluation and adaptation of care delivery strategies to address the challenges faced by patients living with HIV.
### FRIDAY, 4 DECEMBER 2020

*Times are in South African Standard Time (SAST) / Central African Time (CAT)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
<th>Institution/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30</td>
<td>Welcome to Day 5</td>
<td>Catherine Hankins MD, PhD, FRCPC, CM</td>
<td>Amsterdam Institute for Global Health and Development, Canada / The Netherlands</td>
</tr>
<tr>
<td></td>
<td><strong>Session 5 - Distance Learning and Dolutegravir Controversy</strong>&lt;br&gt;Chairs: Anna Laura Ross (Switzerland) and Sam Phiri (Malawi)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:35</td>
<td>Introduction</td>
<td>Anna Laura Ross, PhD</td>
<td>UNITAID, Switzerland</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sam Phiri, DCM, PhD, MSc</td>
<td>Partners in Hope, Malawi</td>
</tr>
<tr>
<td>13:51</td>
<td>Dolutegravir and Weight Gain - Where are We?</td>
<td>François Venter, MBCCH, MMed, FCP (SA), DTM&amp;H</td>
<td>University of the Witwatersrand, South Africa</td>
</tr>
<tr>
<td>14:06</td>
<td>Q &amp; A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:20</td>
<td>Tea Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:35</td>
<td>Mini-Oral Abstract Presentations 3&lt;br&gt;Chairs: Elly Katabira (Uganda) and Peter Kilmarx (United States)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:36</td>
<td>Introduction</td>
<td>Joram Okeng, Uganda</td>
<td>Uganda</td>
</tr>
<tr>
<td>14:39</td>
<td>Adverse Event Notification and Tracking Among HIV Positive Patients on ART: Lessons from A Tele-Health Centre In Kampala</td>
<td>Gift Kamanga, Liberia</td>
<td>Liberia</td>
</tr>
<tr>
<td>14:42</td>
<td>Creating a Safe Space for Key Populations Within Health Facilities: Experience from Montserrado County, Liberia</td>
<td>Chidubem Oraelosi, Nigeria</td>
<td>Nigeria</td>
</tr>
<tr>
<td>14:45</td>
<td>Stakeholder Participation in The Establishment of One-Stop Shops and Key Population-Friendly Facilities: Descriptive Lessons from the FHI 360 GF Project</td>
<td>Selamawit Wolfesenbet, South Africa</td>
<td></td>
</tr>
<tr>
<td>14:51</td>
<td>Cost of Antiretroviral Therapy Services Among Patients Who Achieved Viral Suppression: A Case Study Of 9 ART Clinics in Namibia</td>
<td>Armanda Nangmo, Cameroon</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alarming Burden of Dual-Class HIV-1 Drug Resistance Among Adolescents Calls for Innovative Antiretroviral Strategies: Baseline Findings from the Ready-Study (EDCTP TMA 1027)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Title</td>
<td>Speaker(s)</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------------------</td>
<td></td>
</tr>
<tr>
<td>14:54</td>
<td>Positive Effects of Intensified Preventive Calls/Home Visits on Early Retention Among Adults Newly Initiated on Antiretroviral Therapy in Zambézia Province, Mozambique</td>
<td>José Tique, Mozambique</td>
<td></td>
</tr>
<tr>
<td>14:57</td>
<td>Short-Cycle Therapy in HIV-Infected Adults: 4 days on / 3 days off with Combinations Containing Rilpivirine</td>
<td>Dora Luise, Italy</td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>Transcriptional Analysis of Lymph Node Derived Follicular CD4 T Cells Reveal Novel Phenotypic Markers and Functions of T Follicular Regulatory (TFR) Cells</td>
<td>Bongiwe Mahlobo, South Africa</td>
<td></td>
</tr>
<tr>
<td>15:03</td>
<td>Q &amp; A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:20</td>
<td>Tea Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:35</td>
<td>Symposium 5 - IAS - “Getting to the Heart of Stigma: What does it take to have an impact at scale?” Chair: Lucy Stackpool-Moore (Switzerland)</td>
<td>Adeeba Kamarulzaman Malaysia, Edwin Cameron South Africa, Kate Thomson Switzerland, Thomas Muchimba Buttenschen Denmark, Laura Ferguson United States, Rt Hon Given Katuta Zambia</td>
<td></td>
</tr>
<tr>
<td>16:20</td>
<td>Closing Session</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:25</td>
<td>Joep Lange Award</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:25</td>
<td>Anne-Marie Nitschke</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Ministry of Health and Social Services, Namibia

Ismael Katjite
National Technical Advisory Committee of the HIV/AIDS response, Namibia

Elly Katabira, MD, FRCP - Co-Chair
Makerere University College of Health Sciences, Uganda

Catherine Hankins MD, PhD, FRCP, CM - Scientific Chair
Amsterdam Institute for Global Health and Development, Canada / The Netherlands
Acknowledgements

CORPORATE SUPPORT

GOLD LEVEL

abbvie

Johnson & Johnson

BRONZE LEVEL

MSD

gsk

ViiV Healthcare

Working together in HIV

PRINCIPLE SUPPORTER LEVEL

NIH

Fogarty

National Institute of Allergy and Infectious Diseases, National Institutes of Health

CONTRIBUTOR LEVEL

anRS

Agence autonome de l’Inserm

INTEREST 2020 - Programme Book
FOR THE 38 MILLION UNTIL IT’S ZERO

WE ARE HERE UNTIL THE DAY WE BEAT HIV

POSI+IVELY COMMITTED
...together, for 35 years and counting
We blend ☏️, Science and Ingenuity to profoundly change the trajectory of health for humanity.

Johnson & Johnson presents a virtual symposium on the latest innovative developments in the prevention and treatment of HIV.

Monday, 30 November 2020
15:35 – 16:20 SAST

Annual INTEREST Conference

Our Mission
End HIV transmission by accelerating adoption of transformational innovation in resource limited settings

Our Vision
#MakeHIVHistory

Learn more at www.jnj.com/gph and follow us @JNJGlobalHealth
At AbbVie, we strive to make a remarkable impact on the lives of patients.

We are a global, research-based biopharmaceutical company committed to discovering, developing and delivering innovative new medicines with distinct and compelling benefits for people. Today, our medicines help 52 million* people living in more than 175 countries, and we are making significant advancements with a robust pipeline of potential new medicines.

We are a passionate, diverse and inclusive organization with a culture that supports the best ideas, wherever they originate. We bring people together because we know that collaboration is the key to breaking barriers and exploring new frontiers in science. We take smart risks that lead to transformative breakthroughs and can change lives for people all over the globe.

Our commitment to making a remarkable impact doesn’t end at developing medicines; it begins there. We provide broader support to our patients and help address the health needs of underserved communities. We strive to protect our environment and to make a positive impact in the areas where we live and work.

*52 million is the total number of patients served by AbbVie products in 2019.